• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association of psoriasis and stroke in end-stage renal disease patients
CONCLUSIONS: Contrary to prior research in the general population, psoriasis in ESRD patients was not associated with the risk of stroke after controlling for various demographic and clinical parameters. Our finding emphasizes the importance of controlling for a variety of factors in population studies examining associations of diseases and risk factors.PMID:37716600 | DOI:10.1016/j.amjms.2023.09.014
Source: The American Journal of the Medical Sciences - September 16, 2023 Category: General Medicine Authors: Naomi Siddiquee Jennifer L Waller Stephanie L Baer Azeem Mohammed Sarah Tran Sandeep Padala Lufei Young Mufaddal Kheda Wendy B Bollag Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Pregnancy-Associated Takotsubo Cardiomyopathy Hospitalizations in the United States
Am J Physiol Heart Circ Physiol. 2023 Jul 7. doi: 10.1152/ajpheart.00262.2023. Online ahead of print.ABSTRACTTakotsubo cardiomyopathy (TCM) is most common in postmenopausal women aged ≥ 50 years but also affects pregnant individuals. However, there are no national estimates on the prevalence, timing of occurrence, correlates, and outcomes of Pregnancy-associated TCM. Using the Nationwide Inpatient Sample (NIS: 2016-2020), we describe rates of pregnancy-associated TCM hospitalizations among 13 - 49 years old pregnant individuals in the United States by selected demographic, behavioral, hospital, and clinical characteristi...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 7, 2023 Category: Physiology Authors: Mulubrhan F Mogos Soojung Ahn James M Muchira Sarah Osmundson Mariann R Piano Source Type: research

In-hospital stroke and mortality trends after left ventricular assist device implantation in the United States from 2017 to 2019
CONCLUSIONS: Our study found a significant downtrend in the in-hospital mortality rates among patients with LVAD without substantial changes in stroke rate trends over the study timeframe. As stroke rates remained steady, we hypothesize that improved management along with better control of blood pressure, could have played an important role in survival benefit over the study time frame.PMID:37387231 | DOI:10.1177/03913988231183723
Source: The International Journal of Artificial Organs - June 30, 2023 Category: Transplant Surgery Authors: Jose Lopez Justin Mark Waseem Wahood Nader Lamaa Mauricio Danckers Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10